Search News Archives
Special Offers and Promotions
Brochures & Literature
Conferences | Events
Excellence in Science and Technology award for Sygnature Discovery
Sygnature Discovery, a leading provider of integrated drug discovery services to pharmaceutical and biotech companies has won the award for Excellence in Science and Technology at the annual Nottingham Post Business Awards.
Sygnature flew the flag for Nottingham’s growing life science industry when the team received the winner’s prize sponsored by leading law firm, Geldards. The company was selected and judged on the quality of its science, commitment to innovation and business sustainability, in the drive to discover the medicines of the future.
As the UK Pharmaceutical industry continues to downsize, Sygnature has experienced an unprecedented demand for its integrated drug discovery services, resulting in an average increase in turnover of 20% per annum for the past 3 years. Last year, new projects were won from US West Coast biotechs and pharmaceutical companies located in the UK and mainland Europe. The company occupies its own ultra-modern laboratories in Biocity Nottingham, the UK’s largest bioscience business incubator. With more laboratory and office facilities currently under construction, Sygnature Discovery is set to reach 100 employees by the end of 2013.
David Williams, Chairman of award sponsors Geldards explained: “We were delighted to sponsor the Award as Geldards has always been committed to supporting innovative ways of thinking that both boost the UK economy and improve people’s lives”.
He added: “Sygnature Discovery is an outstanding company and a deserved winner of the Award. It is one of a number of companies that superbly illustrate that the Nottingham area is at the forefront of the UK’s efforts to rejuvenate through science and technology”.
Dr Simon Hirst, Sygnature’s CEO said: “This award recognises the difficult work carried out throughout our laboratories in Nottingham. The scientists here face tough challenges in the discovery of new drug molecules so it is very gratifying to have their hard work recognised in this way”